HOME >> MEDICINE >> NEWS
Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinson's patients

A national clinical trial with 80 Parkinson's disease patients has shown that high dosages of a naturally occurring compound, coenzyme Q10, slowed by 44 percent the progressive deterioration in function that occurs in the disease. The greatest benefit was seen in everyday activities such as feeding, dressing, bathing and walking.

The study's coordinators caution that while encouraging, the therapy needs to be tested in a larger trial with hundreds of patients before this treatment can be recommended.

Published in the Oct. 15, 2002 issue of the American Medical Association's Archives of Neurology, the study was conducted at 10 sites by the Parkinson Study Group, under the direction of principal investigator Clifford Shults, M.D., professor of neurosciences, University of California, San Diego (UCSD) School of Medicine, and chief of the Neurology Service at the VA San Diego Healthcare System. Parkinson's disease is a degenerative disorder of the brain in which patients develop tremor, slowness of movement and stiffness of muscles. It affects approximately 1 percent of Americans over the age of 65. Although certain drugs, such as levodopa, can reduce the symptoms of Parkinson's disease, no treatment has been shown to slow the progressive deterioration in function.

The selection of coenzyme Q10 as a potential treatment for Parkinson's was based on work carried out over the past decade by Shults, Richard Haas, M.D., UCSD professor of neurosciences, and Flint Beal, M.D., professor and chair of neurology, Weill Medical College of Cornell University.

Shults explained that mitochondria produce the energy-containing molecules that supply energy to chemical reactions in cells and that coenzyme Q10 plays an integral role in that process. He further explained that coenzyme Q10 is also a potent antioxidant. Over the past several years, research by Shults, Haas and Beal showed that mitochondrial function is impaired in patients with Park
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2002


Page: 1 2 3 4

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
(Date:8/1/2014)... Home Care Assistance of Cincinnati , a ... be recognized as a 2014 Best of Home Care Employer ... providers who rank in the top 50th percentile in one ... conducted by Home Care Pulse. , “The Best of ... best of the best!” says Home Care Pulse Founder and ...
(Date:8/1/2014)... Ticket Down is a reputable source for authentic ... Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; Cross Creek Place ... Luke Bryan is currently out on his summer “That’s My ... Bryan is responsible for one of the most popular country ... just because the summer is over doesn’t mean that when ...
(Date:8/1/2014)... of Bioengineering and Nanotechnology (IBN), Singapore General Hospital ... co-developed the first molecular test kit that can ... patients. This breakthrough was recently reported in ... , According to IBN Executive Director Professor ... molecular diagnostics and cancer research, we have developed ...
(Date:8/1/2014)... August 01, 2014 CapsCanada, a ... opening of a new K-CAPS® (HPMC capsules) manufacturing ... announced expansion plans last year while experiencing growing ... Martin, General Manager, “KCAPS® are currently sold in ... added that: “Compared to other HPMC capsules, K-CAPS® ...
(Date:8/1/2014)... Hills, CA (PRWEB) August 01, 2014 ... has found that carbohydrates may contribute to the ... genetically predisposed to the disease. The study was authored ... it, carbohydrates were found to cause intestinal cells to ... more susceptible to colorectal cancer. , “What’s interesting ...
Breaking Medicine News(10 mins):Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Carbs May Contribute to Colon Cancer 2
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... Lazarus Effect, a medical device company focused ... removal of blood clots, announced the closing of a ... EU commercialization of several approved Lazarus Effect devices, as ... Lazarus Cover™ in the United States ... the value of our novel, platform technology as well ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2
Cached News: